Trametinib Safe, Effective for Juvenile Myelomonocytic Leukemia
By Elana Gotkine HealthDay Reporter
TUESDAY, June 18, 2024 -- For children with relapsed or refractory juvenile myelomonocytic leukemia (JMML), trametinib is safe and effective, according to a study published online June 12 in Cancer Discovery.
Noting that patients with relapsed or refractory (advanced) JMML have poor outcomes, Elliot Stieglitz, M.D., from the University of California San Francisco, and colleagues examined the safety and efficacy of trametinib, an oral MEK1/2 inhibitor, in a phase 2 trial involving 10 patients with advanced JMML.
The researchers found that the objective response rate was 50 percent. After receiving trametinib, four patients with refractory disease proceeded to hematopoietic stem cell transplantation (HSCT). Three additional patients completed all 12 cycles of trametinib permitted in the study and then received trametinib off-protocol, without undergoing HSCT. The remaining three patients had progressive disease; by the end of cycle 2, two of these patients had molecular evolution.
"Our trial offered an option for parents who did not want to subject their children to a repeat HSCT and, in some cases, helped patients avoid HSCT entirely," Stieglitz said in a statement. "The findings suggest that trametinib may be a less toxic alternative to HSCT for select patients."
Two authors disclosed ties to the biopharmaceutical industry; Novartis provided trametinib for the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Statin Use Improves Outcomes in Chronic, Small Lymphocytic Leukemia
WEDNESDAY, April 30, 2025 -- For patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), statin use is associated with improved survival, regardless...
Disparities Identified in Leukemia Incidence, Mortality in Florida
TUESDAY, March 25, 2025 -- There are racial and geographic disparities in the incidence of and mortality from adult leukemia in Florida, where the incidence of leukemia is the...
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
MONDAY, March 10, 2025 -- For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.